Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
79% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. CRMD: No Debt )
CRMD' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: No Debt

Equity to Asset 0.82
CRMD's Equity to Asset is ranked higher than
84% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRMD: 0.82 )
CRMD' s 10-Year Equity to Asset Range
Min: -1.36   Max: 0.82
Current: 0.82

-1.36
0.82
F-Score: 5
Z-Score: 8.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7785.85
CRMD's Operating margin (%) is ranked higher than
52% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. CRMD: -7785.85 )
CRMD' s 10-Year Operating margin (%) Range
Min: -245750   Max: -245750
Current: -7785.85

Net-margin (%) -20447.17
CRMD's Net-margin (%) is ranked higher than
50% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CRMD: -20447.17 )
CRMD' s 10-Year Net-margin (%) Range
Min: -456650   Max: -456650
Current: -20447.17

ROA (%) -375.41
CRMD's ROA (%) is ranked lower than
51% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. CRMD: -375.41 )
CRMD' s 10-Year ROA (%) Range
Min: -443.24   Max: -116.99
Current: -375.41

-443.24
-116.99
ROC (Joel Greenblatt) (%) -23715.52
CRMD's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. CRMD: -23715.52 )
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -77336.36   Max: -23975.61
Current: -23715.52

-77336.36
-23975.61
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CRMD Guru Trades in Q1 2014

Paul Singer 781,440 sh (unchged)
» More
Q2 2014

CRMD Guru Trades in Q2 2014

Paul Singer 781,440 sh (unchged)
» More
Q3 2014

CRMD Guru Trades in Q3 2014

Paul Singer 781,440 sh (unchged)
» More
Q4 2014

CRMD Guru Trades in Q4 2014

Paul Singer 781,440 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 22.70
CRMD's P/B is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CRMD: 22.70 )
CRMD' s 10-Year P/B Range
Min: 0   Max: 22.4
Current: 22.7

0
22.4
P/S 1059.70
CRMD's P/S is ranked higher than
60% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. CRMD: 1059.70 )
CRMD' s 10-Year P/S Range
Min: 0   Max: 10793.6
Current: 1059.7

0
10793.6
EV-to-EBIT -13.28
CRMD's EV-to-EBIT is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CRMD: -13.28 )
CRMD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -13.28

Current Ratio 5.53
CRMD's Current Ratio is ranked higher than
78% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CRMD: 5.53 )
CRMD' s 10-Year Current Ratio Range
Min: 0.1   Max: 10.33
Current: 5.53

0.1
10.33
Quick Ratio 4.98
CRMD's Quick Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CRMD: 4.98 )
CRMD' s 10-Year Quick Ratio Range
Min: 0.1   Max: 10.33
Current: 4.98

0.1
10.33
Days Inventory 267.41
CRMD's Days Inventory is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CRMD: 267.41 )
CRMD' s 10-Year Days Inventory Range
Min: 72.28   Max: 72.28
Current: 267.41

Days Sales Outstanding 158.40
CRMD's Days Sales Outstanding is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. CRMD: 158.40 )
CRMD' s 10-Year Days Sales Outstanding Range
Min: 365   Max: 365
Current: 158.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.80
CRMD's Price/Net Cash is ranked higher than
77% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. CRMD: 26.80 )
CRMD' s 10-Year Price/Net Cash Range
Min: 2.11   Max: 23.25
Current: 26.8

2.11
23.25
Price/Net Current Asset Value 24.40
CRMD's Price/Net Current Asset Value is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. CRMD: 24.40 )
CRMD' s 10-Year Price/Net Current Asset Value Range
Min: 2.11   Max: 23.25
Current: 24.4

2.11
23.25
Price/Tangible Book 22.50
CRMD's Price/Tangible Book is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. CRMD: 22.50 )
CRMD' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 15.17
Current: 22.5

2.05
15.17
Earnings Yield (Greenblatt) -7.00
CRMD's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CRMD: -7.00 )
CRMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -34.6   Max: 0
Current: -7

-34.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix, Inc. was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CorMedix (CRMD) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape Feb 12 2015
CORMEDIX INC. Files SEC form 8-K/A, Financial Statements and Exhibits Feb 09 2015
CORMEDIX INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 06 2015
CorMedix (CRMD) Looks Good: Stock Moves 9.2% Higher - Tale of the Tape Feb 02 2015
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2015
FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.'s Lead Product Candidate in the U.S. Jan 29 2015
CORMEDIX INC. Files SEC form 8-K, Other Events Jan 20 2015
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 15 2015
CorMedix Inc. Receives Fast Track Designation for Neutrolin® Jan 15 2015
CorMedix (CRMD) Shows Strength: Stock Moves Up 14.6% - Tale of the Tape Jan 15 2015
CORMEDIX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 12 2015
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 23 2014
CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement in the Kingdom of... Dec 23 2014
CORMEDIX INC. FILES REQUEST WITH FDA FOR QIDP DESIGNATION FOR NEUTROLIN® Dec 10 2014
NEUTROLIN LABEL EXPANSION APPROVED IN GERMANY Dec 10 2014
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 04 2014
CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin® Dec 04 2014
Neutrolin Label Expansion Approved in Germany Dec 03 2014
CORMEDIX INC. Financials Nov 21 2014
CORMEDIX INC. Files SEC form 10-Q, Quarterly Report Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK